SRT501, a formulation of resveratrol with roughly five times higher bioavailability than the chemical aloneAccording to the scientist on 60 minutes the drug they are testing is in an early stage and still about five years away from being an available product.
There are a long list of clinical trials being conducting throughout the U.S. to test Resveratrol and patients with: Alzheimer's Disease, Colon Cancer, Colorectal Cancer, Insulin Resistance, and Aging (Obesity, Metabolic Syndrome, Diabetes).
One study that should be of particular interest to subscribers of this blog is, a Randomized Trial of a Nutritional Supplement in Alzheimer's Disease. The study is active and open to new enrollment. It is difficult for me to determine if the study is limited to a single location in New York, or if, it is being conducted in multiple locations by the Department of Affairs. I will find out and follow up on the blog.
A second study that should be of interest to subscribers to this web site is: Pilot Study of the Effects of Resveratrol Supplement in Mild-to-Moderate Alzheimer's Disease. It appears that this is a single location study currently being performed at the Medical College of Wisconsin. I am not sure at the time I am writing if the study is open, ongoing at this time, or closed, as the record has not been updated since August, 2008. I will check into this and find out about the current status.
You can obtain a list of all the current studies being done with Resveratrol by going to Clinicaltrials.gov and entering Resveratrol in the search box. Or click this link and go there.
If you want to know more about Sirtris go here. Sirtris Pharmaceuticals has been acquire by GlaxoSmithKline.
Subscribe to The Alzheimer's Reading Room--via EmailOriginal article the Alzheimer's Reading Room
No comments:
Post a Comment